Predicted protein targets (top 4)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAPK1 | P28482 | 1/20 | 0.34 |
| ▸ | P2RX7 | Q99572 | 1/20 | 0.33 |
| ▸ | JAK2 | O60674 | 1/20 | 0.30 |
| ▸ | BTK | Q06187 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL20408789 | 0.90 | P2RX7 (0.33) | MAPK1P2RX7JAK2BTK | |
| SCHEMBL10159170 | 0.82 | P2RX7 (0.34) | MAPK1P2RX7 | |
| SCHEMBL30486658 | 0.79 | LPL (0.35) | MAPK1P2RX7JAK2BTK | |
| SCHEMBL15335320 | 0.79 | LPL (0.35) | MAPK1P2RX7JAK2BTK | |
| SCHEMBL29780026 | 0.78 | LPL (0.31) | JAK2BTK | |
| SCHEMBL16042255 | 0.78 | LPL (0.31) | JAK2BTK | |
| SCHEMBL17397866 | 0.76 | LMNA (0.37) | MAPK1P2RX7 | |
| SCHEMBL23974414 | 0.75 | GAA (0.39) | MAPK1P2RX7JAK2BTK | |
| SCHEMBL29885660 | 0.75 | GAA (0.39) | MAPK1P2RX7JAK2BTK | |
| SCHEMBL16762235 | 0.74 | JAK2 (0.35) | MAPK1P2RX7JAK2BTK |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11912701-B2 | Protein kinase inhibitors for promoting liver regeneration or reducing or preventing hepatocyte death | HEPAREGENIX GMBH (DE) | 2024-02-27 | — | — | US | disclosed |
| US-11912701-B2 | Protein kinase inhibitors for promoting liver regeneration or reducing or preventing hepatocyte death | HEPAREGENIX GMBH (DE) | 2024-02-27 | — | — | US | disclosed |
| EP-3571200-B1 | PROTEIN KINASE INHIBITORS FOR PROMOTING LIVER REGENERATION OR REDUCING OR PREVENTING HEPATOCYTE DEATH | HEPAREGENIX GMBH (DE) | 2022-06-22 | — | — | EP | disclosed |
| EP-3571200-B1 | PROTEIN KINASE INHIBITORS FOR PROMOTING LIVER REGENERATION OR REDUCING OR PREVENTING HEPATOCYTE DEATH | HEPAREGENIX GMBH (DE) | 2022-06-22 | — | — | EP | disclosed |
| CN-110291089-B | Protein kinase inhibitors for promoting liver regeneration or reducing or preventing liver cell death | 海帕瑞吉尼克斯股份有限公司 | 2022-05-27 | — | — | CN | disclosed |
| US-11040027-B2 | Protein kinase inhibitors for promoting liver regeneration or reducing or preventing hepatocyte death | HEPAREGENIX GMBH (DE) | 2021-06-22 | — | — | US | disclosed |
| US-11040027-B2 | Protein kinase inhibitors for promoting liver regeneration or reducing or preventing hepatocyte death | HEPAREGENIX GMBH (DE) | 2021-06-22 | — | — | US | disclosed |
| WO-2018134254-A1 | PROTEIN KINASE INHIBITORS FOR PROMOTING LIVER REGENERATION OR REDUCING OR PREVENTING HEPATOCYTE DEATH | HEPAREGENIX GMBH (DE) | 2018-07-26 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11040027-B2 | Protein kinase inhibitors for promoting liver regeneration or reducing or preventing hepatocyte death | MAPK4, HNF4A, HGF | MAPK1 25/4885P2RX7 4535/4885JAK2 2305/4885 |
| US-11912701-B2 | Protein kinase inhibitors for promoting liver regeneration or reducing or preventing hepatocyte death | MAPK4, MAPK7, MAPK14 | MAPK1 5/4885P2RX7 4096/4885JAK2 640/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.